Fitting curves of UCS in different rock sizes. by Gaojian Hu (11457537)

“…The research results indicate that: (1) the uniaxial compressive strength decreases with the increase of the rock bridge angle, showing a power function relationship; (2) The uniaxial compressive strength decreases with the increase of rock size and tends to stabilize when the rock size is greater than 350 mm, showing a significant size effect. (3) The fluctuation coefficient of compressive strength increases with the increase of rock bridge angle and decreases with the increase of rock size; When the rock size is 350 mm, the fluctuation coefficient is less than 5%; (4) The characteristic compressive strength and characteristic size both increase with the increase of the rock bridge angle.…”

UCS under different rock size. by Gaojian Hu (11457537)

“…The research results indicate that: (1) the uniaxial compressive strength decreases with the increase of the rock bridge angle, showing a power function relationship; (2) The uniaxial compressive strength decreases with the increase of rock size and tends to stabilize when the rock size is greater than 350 mm, showing a significant size effect. (3) The fluctuation coefficient of compressive strength increases with the increase of rock bridge angle and decreases with the increase of rock size; When the rock size is 350 mm, the fluctuation coefficient is less than 5%; (4) The characteristic compressive strength and characteristic size both increase with the increase of the rock bridge angle.…”

Relationship between CCS and rock bridge angle. by Gaojian Hu (11457537)

“…The research results indicate that: (1) the uniaxial compressive strength decreases with the increase of the rock bridge angle, showing a power function relationship; (2) The uniaxial compressive strength decreases with the increase of rock size and tends to stabilize when the rock size is greater than 350 mm, showing a significant size effect. (3) The fluctuation coefficient of compressive strength increases with the increase of rock bridge angle and decreases with the increase of rock size; When the rock size is 350 mm, the fluctuation coefficient is less than 5%; (4) The characteristic compressive strength and characteristic size both increase with the increase of the rock bridge angle.…”

Fitting curve of CCS and rock bridge angle. by Gaojian Hu (11457537)

“…The research results indicate that: (1) the uniaxial compressive strength decreases with the increase of the rock bridge angle, showing a power function relationship; (2) The uniaxial compressive strength decreases with the increase of rock size and tends to stabilize when the rock size is greater than 350 mm, showing a significant size effect. (3) The fluctuation coefficient of compressive strength increases with the increase of rock bridge angle and decreases with the increase of rock size; When the rock size is 350 mm, the fluctuation coefficient is less than 5%; (4) The characteristic compressive strength and characteristic size both increase with the increase of the rock bridge angle.…”

Curve fitting of rock bridge angle and UCS. by Gaojian Hu (11457537)

“…The research results indicate that: (1) the uniaxial compressive strength decreases with the increase of the rock bridge angle, showing a power function relationship; (2) The uniaxial compressive strength decreases with the increase of rock size and tends to stabilize when the rock size is greater than 350 mm, showing a significant size effect. (3) The fluctuation coefficient of compressive strength increases with the increase of rock bridge angle and decreases with the increase of rock size; When the rock size is 350 mm, the fluctuation coefficient is less than 5%; (4) The characteristic compressive strength and characteristic size both increase with the increase of the rock bridge angle.…”

DataSheet1_Amygdalin as a chemoprotective agent in co-treatment with cisplatin.PDF by Panayiota Christodoulou (13832038)

“…As attested by flow cytometry, combination treatment was associated with decreased the percentage of late apoptotic cells compared with monotherapy (fold-change of decrease = 1.6 and 4.5 for 15 and 20 μΜ, respectively). …”

The changing trends of <i>f</i>_<i>i</i>, <i>i</i> ∈ {1, 2, 3, 4} with <i>v</i> for the Moran process (first row) and the Wright-Fisher process (second row) when <i>u</i>... by Yanling Zhang (6561)

“…For all <i>r</i>, The curve of <i>f</i>₄ with <i>v</i> (fourth column) has an increasing trend with a small perturbation near <i>v</i> = 0.01. …”

Electrochemistry as a Complementary Technique for Revealing the Influence of Reducing Agent Concentration on AgNPs. by Sapokazi Timakwe (14127576)

“…This process ended up in the formation of large aggregates that decrease the active surface area and therefore result in a significant decrease in their unique properties. …”

Data_Sheet_6_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Table_2_Age-Dependent Assessment of Genes Involved in Cellular Senescence, Telomere, and Mitochondrial Pathways in Human Lung Tissue of Smokers, COPD, and IPF: Associations With SA... by Krishna P. Maremanda (9356819)

“…Aging plays an important role in various infectious diseases including the SARS-CoV-2 infection. Lung immunoblot analysis of smokers, COPD and IPF subjects revealed increased abundance of proteases and receptor/spike protein like TMPRSS2, furin, and DPP4 in association with a slight increase in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor ACE2 levels.…”

Data_Sheet_4_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Data_Sheet_2_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Data_Sheet_8_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Table_1_Age-Dependent Assessment of Genes Involved in Cellular Senescence, Telomere, and Mitochondrial Pathways in Human Lung Tissue of Smokers, COPD, and IPF: Associations With SA... by Krishna P. Maremanda (9356819)

“…Aging plays an important role in various infectious diseases including the SARS-CoV-2 infection. Lung immunoblot analysis of smokers, COPD and IPF subjects revealed increased abundance of proteases and receptor/spike protein like TMPRSS2, furin, and DPP4 in association with a slight increase in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor ACE2 levels.…”

Data_Sheet_7_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Data_Sheet_1_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Data_Sheet_3_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Amide Proton Transfer Imaging of Diffuse Gliomas: Effect of Saturation Pulse Length in Parallel Transmission-Based Technique - Fig 2 by Osamu Togao (470739)

“…MTR_asym (<b>A</b>) of tumor was decreased with the saturation length in lower frequency range (1–2 ppm), but equivalent at 3.5 ppm. …”

Illustrative representation of the results from the extinction portion of the behavioural testing for STD and IMP animals; blue bars represent the initial testing day and white bar... by Harleen Hehar (810999)

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-co... by Tadao Akizawa (316095)

“…<div><p>Background</p><p>Evocalcet has been developed as a new calcimimetic agent for hemodialysis (HD) patients with secondary hyperparathyroidism (HDSHPT), eliciting fewer gastrointestinal symptoms and drug interactions. …”